Braveheart Bio, Inc. (BRVE) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $0.00; Retained Earnings (Accumulated Deficit)USD $-95.91M; Stockholders' Equity Attributable to ParentUSD $-95.91M.
- 2026-03-31: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Retained Earnings (Accumulated Deficit)USD (m); Stockholders' Equity Attributable to ParentUSD $-78.39M.
- 2025-12-31: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $179.00K; Retained Earnings (Accumulated Deficit)USD $-66.05M; Stockholders' Equity Attributable to ParentUSD $-65.87M.
- 2025-06-30: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Retained Earnings (Accumulated Deficit)USD (m); Stockholders' Equity Attributable to ParentUSD $-477.00K.
Braveheart Bio, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.00K | $0.00 | $-95.91M | $-95.91M | 3 month · $1.09M | 3 month · $3.62M |
| 2026-03-31 | (m) | (m) | (m) | $-78.39M | 3 month · $1.76M | (m) |
| 2025-12-31 | $1.00K | $179.00K | $-66.05M | $-65.87M | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | $-477.00K | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | $-99.00K | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | $0.00 | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |